Frequently Asked Questions
The market is segmented based on , By Class (Serotonin Receptor Antagonists (5-HT3 RAS), Neurokinin-1 Receptor Antagonist (NK1 RAS), 5HT3 RA/NK1 RA Combination, Corticosteroids, Olanzapine, Others), Type of Emesis (Acute, Delayed, Anticipatory, Breakthrough, Refractory, Chronic, Others), Application (Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, Other), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Emetogenic Drugs Market size was valued at USD 1371.50 USD Million in 2022.
The Global Emetogenic Drugs Market is projected to grow at a CAGR of 14.2% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
